Several innovative medications are reshaping blood sugar care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide standing out promising options. Retatrutide, a dual GIP and GLP-1 site stimulant, shows remarkable fat reduction and enhanced glycemic control. Cagrillintide, a GLP-1 stimulant, is now in clinical studies, showing favorable o